Q1235. How to translate biopharmaceutical and chemical patent records for FDA approval?

Answered by the NYC Visa & Translation certified translation team

Biopharmaceutical and chemical patent translations for regulatory approval sit at the intersection of patent law and regulatory science, and each has its own exactness demands. The patent side: the claims define the legal scope — in a chemical or biopharmaceutical patent, the claims contain the structures, the ranges, the process parameters, and the Markush groups, and every element is transcribed exactly (a numerical range mistranslated narrows or broadens the monopoly; a substituent group listed wrongly voids a claim). The chemical nomenclature follows IUPAC exactly, the biological sequences are reproduced character-exact (never retyped — copied and verified), and the CAS numbers, the sequence listing references, and the deposit numbers are carried across unchanged. The regulatory side (the FDA or Thai FDA submission): the dossier follows the CTD or ACTD structure, and the translated content must map to the structure's modules; the clinical and nonclinical content uses the standard terminologies (MedDRA for adverse events, the pharmacopoeial names for substances); and the manufacturing content (the CMC module) uses the process terminology exactly as the validated process describes it. Points that matter: the patent and the regulatory dossier are different documents with different audiences — a patent's claim language is not the dossier's language, and content is not copied between them casually; the priority dates and the filing references in the patent must be exact; and for the PCT national phase, the deadline (30 months from priority) is unforgiving, so the translation is scheduled with margin. Practice points: use translators with both the chemistry and the patent-drafting background; and the client's patent attorney reviews the claims translation before filing.